6-Year Data Sustain Adjuvant Olaparib Benefit in BRCA1/2+, HER2- Breast Cancer
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to 6-year data from the OlympiA trial.